Please login to the form below

Not currently logged in
Email:
Password:

New medical animation company launched

Fusion Medical Animation, a new company specialising in drug mode of action (MOA) animation has been founded by Simon Reid, the former director of production at Random42
Fusion Medical Animation, a new company specialising in drug mode of action (MOA) animation for the pharma, research and healthcare industries has been founded by Simon Reid, the former director of production at Random42. 

MOA animations communicate the biochemical interaction through which a drug substance produces its pharmacological effect. Targeted at physicians, Fusion's animations can lead to greater awareness and adoption of clients' products.

With photo-real animation now common place in film, television and increasingly online, pharma clients are beginning to expect this sort of quality animation and CGI, to explain and market their new drugs and products.

An example of Fusion's MOA animation



Fusion's unique position allows them to combine feature film quality graphics, along with scientifically accurate pharmaceutical MOA expertise.

Before moving to the pharmaceutical industry as director of production at a leading MOA animation agency, Reid spent many years setting up and running various visual effects departments for factual broadcast. 

In addition to their work in the pharmaceutical arena, Fusion has worked on the landmark BBC science series "First Life" presented by Sir David Attenborough as well as producing the medical/science shots for another Attenborough documentary, "Flying Monsters", a stereoscopic production for the new Sky 3D channel and IMAX theatres. 

5th January 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics